During oncology clinical trials, if a patient’s disease progresses, they are often given the opportunity to cross over to active treatment. This alleviates ethical issues associated with placebo controls, but how does it effect the analysis of overall survival and cost-effectiveness? Read more here. (Source: Elsevier, Value In Health 17).
You are here: / / How Does Crossover Affect Overall Survival Analysis In Randomized Controlled Trials